CMPX
Compass TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
Current thesis
The constructive interpretation is that the April BTC update showed statistically significant ORR and PFS benefit, while the May 5 earnings release reiterated a planned FDA meeting, possible BLA timing later in 2026, and $195 million of cash expected to fund operations into 2028 [#8-K-2026-05-05] [#10-Q-2026-05-05]. If FDA focuses on the totality of efficacy and the crossover issue is manageable, the post-collapse equity value leaves room for recovery.
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
CMPX remains a low-coverage small-cap biotech, which increases volatility and lowers confidence that consensus targets fully reflect the latest clinical debate.
Momentum
35
Value
41
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.90 · Bull $4.50 · Bear $0.80
Data freshness
Prices
As of 2026-07-21
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-21 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-21
Investment thesis
As of 2026-07-21
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.50
Why
Momentum35 · Δ7d -
Value41 · Δ7d +0.1
Sentiment44 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
35
26% active weight
Current posture
7d trendSoftening
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-0.0
Sentiment
44
34% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 34.9 / Value 41.1 / Sentiment 44.2
Fundamentals (TTM)As of 2026-07-21
Fundamentals (TTM)
As of 2026-07-21
Market Cap
$378.19M
Beta
1.27
Shares Out
180.09M
P/E (TTM) · Derived
-5.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.67
Rev YoY
-100.0%
EPS YoY
-18.3%
Gross Margin
-94.6%
Op Margin
-7273.4%
Net Debt
-$199.08M
Current Ratio
19.04
As of 2026-07-21 • Updated nightlySource: Internal modelMethodology